In Vivo Targeted Metabolomic Profiling of Prostanit, a Novel Anti-PAD NO-Donating Alprostadil-Based Drug

Prostanit is a novel drug developed for the treatment of peripheral arterial diseases. It consists of a prostaglandin E(1) (PGE(1)) moiety with two nitric oxide (NO) donor fragments, which provide a combined vasodilation effect on smooth muscles and vascular spastic reaction. Prostanit pharmacokinet...

Descripción completa

Detalles Bibliográficos
Autores principales: Shestakova, Ksenia M., Moskaleva, Natalia E., Mesonzhnik, Natalia V., Kukharenko, Alexey V., Serkov, Igor V., Lyubimov, Igor I., Fomina-Ageeva, Elena V., Bezuglov, Vladimir V., Akimov, Mikhail G., Appolonova, Svetlana A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764275/
https://www.ncbi.nlm.nih.gov/pubmed/33322104
http://dx.doi.org/10.3390/molecules25245896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764275/
https://www.ncbi.nlm.nih.gov/pubmed/33322104
http://dx.doi.org/10.3390/molecules25245896

Ejemplares similares